The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients.
Lu Meng, Jianfang Xu, Ying Ye...
https://pubmed.ncbi.nlm.nih.gov/34621270/Actively Recruiting
Led by Yonsei University · Updated on 2024-11-01
33
Participants Needed
1
Research Sites
48 weeks
Total Duration
Researchers are evaluating the combination of atezolizumab and bevacizumab with stereotactic body radiotherapy SBRT for patients with advanced hepatocellular carcinoma. This study aims to improve the treatment response rate of the current first-line chemotherapy, which has shown low response rates. Participants have advanced liver cancer that cannot be operated on and are eligible for this combination therapy. Participants will receive SBRT targeting one to five sites of primary or metastatic cancer lesions within two months before or after starting the atezolizumab-bevacizumab combination therapy. The study includes several visits screening, during and after SBRT, chemotherapy cycles, and follow-up visits lasting up to 36 months to monitor treatment effects and safety. During the study, participants will undergo medical history reviews, physical exams, imaging tests like CT or MRI, blood tests including tumor markers and biomarkers, stool microbiota analysis, and quality of life questionnaires. Researchers will monitor adverse events and assess progression-free survival at 6 months as the primary outcome, alongside secondary outcomes such as overall survival, tumor response, and safety over 36 months.
CONDITIONS
Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma
H
Hwakyung BYUN, Phd
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Yonsei University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 9 weeks
Participants receive stereotactic body radiotherapy and atezolizumab-bevacizumab combination therapy for advanced hepatocellular carcinoma.
4 visits during treatment including baseline, during radiotherapy, 1 week after radiotherapy, and after 2 cycles of chemotherapy
Duration - 3 to 36 months
Participants are monitored for adverse events, treatment effectiveness, and quality of life after completing treatment.
Regular visits approximately monthly to every few months during follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Lu Meng, Jianfang Xu, Ying Ye...
https://pubmed.ncbi.nlm.nih.gov/34621270/Robert Timmerman
https://pubmed.ncbi.nlm.nih.gov/34919882/Jason J Luke, Jeffrey M Lemons, Theodore G Karrison...
https://pubmed.ncbi.nlm.nih.gov/29437535/Stanley H Benedict, Kamil M Yenice, David Followill...
https://pubmed.ncbi.nlm.nih.gov/20879569/Sandra Demaria, Chandan Guha, Jonathan Schoenfeld...
https://pubmed.ncbi.nlm.nih.gov/33827904/Hwa Kyung Byun, Nalee Kim, Sangjoon Park...
https://pubmed.ncbi.nlm.nih.gov/30989242/Sandra Demaria, Encouse B Golden, Silvia C Formenti
https://pubmed.ncbi.nlm.nih.gov/26270858/Willemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari...
https://pubmed.ncbi.nlm.nih.gov/31294749/Yonsei University
Lead Sponsor